The content on this site is intended for healthcare professionals only
Dr Tanuj Chawla and Dr Giovanni Selvaggi speak to ecancer as part of ASCO GI 2023 on the overall survival analysis of the HERIZON study.
The study evaluated the use of the HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma.
Dr Chawla and Dr Selvaggi explain the background of the trial before talking though the trial design.
Dr Chawla reports that the study was able to achieve 5 months better survival with the vaccine arm as compared to chemotherapy.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
ASCO 2024: Lung cancer highlights
PD-1–refractory advanced melanoma: how do we get to the finish line?
Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC
OncoAlert round up July 28th to August 3rd, 2023
Intra-arterial gemcitabine and IV gemcitabine/nab-paclitaxel show similar SAEs in locally advanced pancreatic cancer
